top of page
  • Jonathan Poyer

Biotech M&A Activity Continues - Biogen Acquired Reata for a 59% Premium




Week Ending July 28th, 2023


  • Biotech: 1 Transaction (1 Follow-On) totaling just over $50 Million

  • Med Tech: 1 Transaction (1 Registered Direct) totaling just under $50 Million


2023 YTD


  • 103 Biotech transactions totaling just over $14 Billion v. 2022: 77 Biotech transactions totaling just under $9 Billion

  • 11 Med Tech transactions totaling just over $700 Million v. 2022: 6 Med Tech transaction just over $400 Million


Private Transactions:


  • Biotech: 136 Transactions / 43European Transactions

  • Med Tech: 81 US Transactions / 28 European Transactions


Notable Transactions:


Biogen acquired Reata Pharma - 7/28/2023 for $7.3B or $172.50/share (59% premium)

Novartis acquired DTx Pharma - 7/17/2023 for $500M

Shionogi acquired Qpex Biopharma - 6/26/2023 for $100M

Eli Lilly acquired Dice Therapeutics - 6/20/203 for $2.4B or $48.00/share (42% premium)

Novartis acquired Chinook Therapeutics - 6/12/2023 for $3.2B or $40.00/share (67% premium)

Gurnet Point Capital, Novo Holdings acquired Paratek Pharmaceuticals - 6/6/2023 for $123M or $2.15/share (9% premium)

13 views0 comments

Comments


bottom of page